Jacek K Pinski, MD, PhD

Title(s)Associate Professor of Medicine
SchoolKeck School of Medicine of Usc
AddressNOR 3440 NTT
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 865 3929
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    GlaxoSmithKline2001Fellowship Award
    Johns Hopkins University2001Fellowship Research Award
    American Association for Cancer Research2001Translational Research Award
    2001Stop Cancer Award Special Seed Award
    2002Wright Award
    2002ACS/IRG Award
    2002Whitney Award
    2002Stop Cancer Research Career Development Award

    Collapse Overview 
    Collapse Overview
    After completing a fellowship at the Johns Hopkins Cancer Center in Baltimore, Dr. Pinski came to the Keck School of Medicine at USC as an Assistant Professor of Medicine. A former Research Assistant Professor at the Endocrine, Polypeptide and Cancer Institute at the Tulane University School of Medicine, Dr. Pinski is currently the Co-Director of the USC/Norris Comprehensive Cancer Center’s Prostate Cancer Research Center.

    Dr. Pinski is also a member of the Rehabilitation Research and Development Section for the United States Department of Veteran Affairs. He has received funding for seven research studies and in 2006 was invited to lecture in Austraila at the 3rd Annual Pacific Rim Breast and Prostate Cancer Meeting. Dr. Pinski has had over 60 peer reviewed articles published and has given presentations all across the globe.

    Collapse Research 
    Collapse Research Activities and Funding
    Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial
    NIH R01CA172436Sep 10, 2014 - Aug 31, 2021
    Role: Co-Principal Investigator
    Targeted Therapy to Receptors for LH-RH in Prostate Cancer
    NIH R01CA148756Sep 1, 2010 - Aug 31, 2015
    Role: Principal Investigator
    AR signaling in Hormone Refractory Prostate Cancer
    NIH R21DK065259Aug 1, 2003 - Jul 31, 2005
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 Oct 01; 7(10):e2437871. Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, Dorff TB, Lerner SP, Thompson I, Agarwal N. PMID: 39374015.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    2. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021 04 01; 27(7):1967-1973. Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. PMID: 33500355; PMCID: PMC8026618.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    3. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol. 2021 04; 87(4):525-532. Thomas JS, El-Khoueiry AB, Maurer BJ, Groshen S, Pinski JK, Cobos E, Gandara DR, Lenz HJ, Kang MH, Reynolds CP, Newman EM. PMID: 33423090; PMCID: PMC8058950.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    4. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68. Gross ME, Agus DB, Dorff TB, Pinski JK, Quinn DI, Castellanos O, Gilmore P, Shih JC. PMID: 32123315; PMCID: PMC7483294.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    5. Expression of the luteinizing hormone receptor (LHR) in ovarian cancer. BMC Cancer. 2019 Nov 15; 19(1):1114. Xiong S, Mhawech-Fauceglia P, Tsao-Wei D, Roman L, Gaur RK, Epstein AL, Pinski J. PMID: 31729966; PMCID: PMC6857310.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    6. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 11 01; 125(21):3853-3863. Barzi A, Lara PN, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S. PMID: 31398279; PMCID: PMC6941667.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    7. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. PMID: 31227432; PMCID: PMC7446934.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    8. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51. Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST. PMID: 30232224; PMCID: PMC6320304.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansCellsCTClinical Trials
    9. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018 06 07; 500(3):621-625. Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K. PMID: 29679564; PMCID: PMC9165692.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    10. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):742-749. Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J. PMID: 28668277.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    11. Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients. Prostate. 2016 10; 76(14):1239-56. Shahabi A, Lewinger JP, Ren J, April C, Sherrod AE, Hacia JG, Daneshmand S, Gill I, Pinski JK, Fan JB, Stern MC. PMID: 27272349; PMCID: PMC9015679.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    12. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clin Genitourin Cancer. 2016 10; 14(5):450-456.e1. Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI. PMID: 26935231; PMCID: PMC7515776.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    13. Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era. Can Urol Assoc J. 2016 Jan-Feb; 10(1-2):E17-22. Shahabi A, Satkunasivam R, Gill IS, Lieskovsky G, Daneshmand S, Pinski JK, Stern MC. PMID: 26858782; PMCID: PMC4729570.
      View in: PubMed   Mentions: 3  
    14. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One. 2015; 10(2):e0117758. Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. PMID: 25693195; PMCID: PMC4333349.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    15. Effects of luteinizing hormone receptor signaling in prostate cancer cells. Prostate. 2015 Feb; 75(2):141-50. Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, Merin NM, Pinski J. PMID: 25393079.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    16. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. PMID: 25278449.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    17. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. PMID: 25245366; PMCID: PMC4234307.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    18. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res. 2014 May 15; 74(10):2857-68. Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B. PMID: 24648349; PMCID: PMC4051204.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    19. LHRH and LHR genotypes and prostate cancer incidence and survival. Int J Mol Epidemiol Genet. 2013; 4(4):228-34. Ingles SA, Liu SV, Pinski J. PMID: 24319538; PMCID: PMC3852642.
      View in: PubMed   Mentions: 7  
    20. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014 Jan; 83(1):159-65. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB. PMID: 24238569.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    21. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. PMID: 24099865.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    22. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI. PMID: 23785174; PMCID: PMC3783857.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    23. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. PMID: 22691503; PMCID: PMC3375600.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    24. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs. 2012 Jun; 21(6):891-9. Engel J, Emons G, Pinski J, Schally AV. PMID: 22577891.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimals
    25. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012 Apr 18; 4(2):420-41. Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI. PMID: 24213318; PMCID: PMC3712699.
      View in: PubMed   Mentions: 6  
    26. Ethnic differences in neuroendocrine expression in prostate cancer tissue. Anticancer Res. 2011 Nov; 31(11):3897-901. Dorff TB, Liu SV, Xiong S, Cai J, Hawes D, Pinski J. PMID: 22110216.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    27. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. Thara E, Dorff TB, Pinski JK, Quinn DI. PMID: 21621934.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    28. Advanced prostate cancer: new agents, new questions. Oncology (Williston Park). 2011 May; 25(6):509, 512. Dorff TB, Pinski J. PMID: 21717905.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs. 2011 Jun; 20(6):769-78. Liu SV, Liu S, Pinski J. PMID: 21449823.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    30. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. PMID: 20142723.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    31. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv. 2011 Jan; 8(1):11-25. Schally AV, Engel JB, Emons G, Block NL, Pinski J. PMID: 21034424.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimals
    32. Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer. Prostate. 2011 Jun 01; 71(8):892-8. Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV. PMID: 21456071.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    33. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate. 2010 Nov 01; 70(15):1692-700. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK. PMID: 20564320.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    34. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 01; 70(12):1359-70. Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J. PMID: 20623636.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    35. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res. 2010 Sep 15; 16(18):4675-80. Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J. PMID: 20670943.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    36. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. PMID: 20484019; PMCID: PMC2898710.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    37. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate. 2009 Jan 01; 69(1):12-23. Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK. PMID: 18814146.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    38. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. PMID: 19213668.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    39. Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. Prostate. 2008 Oct 01; 68(14):1555-60. Mori R, Wang Q, Danenberg KD, Pinski JK, Danenberg PV. PMID: 18651557.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    40. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008 Dec; 102(11):1601-6. Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. PMID: 18782306.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    41. Diet and prostate cancer risk reduction. Expert Rev Anticancer Ther. 2008 Jan; 8(1):43-50. Cheung E, Wadhera P, Dorff T, Pinski J. PMID: 18095882.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    42. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res. 2008 Jan-Feb; 28(1B):425-30. Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski JK. PMID: 18383880.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    43. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. PMID: 18272025.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    44. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol. 2007 Oct; 38(10):1547-52. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J. PMID: 17640713.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
    45. Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Rev Anticancer Ther. 2006 Nov; 6(11):1639-51. Dorff TB, Quek ML, Daneshmand S, Pinski J. PMID: 17134367.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    46. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol. 2006 Oct; 26(19):7331-41. Jia L, Shen HC, Wantroba M, Khalid O, Liang G, Wang Q, Gentzschein E, Pinski JK, Stanczyk FZ, Jones PA, Coetzee GA. PMID: 16980632; PMCID: PMC1592894.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    47. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate. 2006 Aug 01; 66(11):1136-43. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV. PMID: 16652383.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    48. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology. 2006 Jun; 67(6):1247-52. Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. PMID: 16697447.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    49. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG. PMID: 16221056.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    50. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther. 2005 Jul; 4(7):1105-13. Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn DI, Neamati N. PMID: 16020668.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    51. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 01; 65(11):4623-32. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. PMID: 15930280.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    52. Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology. 2005 May; 65(5):1008-12. Daneshmand S, Dorff TB, Quek ML, Cai J, Pike MC, Nichols PW, Pinski J. PMID: 15882754.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    53. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer. 2005 Apr; 41(6):932-40. Pinski J, Dorff TB. PMID: 15808959.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    54. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005 Apr-Jun; 4(2):91-7. Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, Conti PS. PMID: 16105512.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    55. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004 Dec; 172(6 Pt 1):2252-5. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG. PMID: 15538242.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    56. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation. Prostate. 2004 Nov 01; 61(3):253-9. Wang Q, Horiatis D, Pinski J. PMID: 15368468.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    57. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer. 2004 Sep 10; 111(4):508-13. Wang Q, Horiatis D, Pinski J. PMID: 15239127.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    58. A new screening system for proliferation-independent anti-cancer agents. Cancer Lett. 2004 Jul 08; 210(1):119-24. Horiatis D, Wang Q, Pinski J. PMID: 15172129.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    59. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol. 2003 Dec; 60(6):395-400. Jadvar H, Kherbache HM, Pinski JK, Conti PS. PMID: 14690256.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    60. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. Jadvar H, Pinski JK, Conti PS. PMID: 12883728.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    61. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Res. 2002 Feb 15; 62(4):986-9. Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. PMID: 11861369.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    62. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res. 2001 Sep 01; 61(17):6372-6. Pinski J, Parikh A, Bova GS, Isaacs JT. PMID: 11522628.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    63. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer. 1998 Mar 01; 82(5):909-17. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, Armatis P. PMID: 9486581.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    64. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate. 1997 Aug 01; 32(3):164-72. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV. PMID: 9254895.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    65. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer. 1997 Jun; 33(7):1141-8. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV. PMID: 9376196.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    66. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci U S A. 1997 May 27; 94(11):5810-3. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. PMID: 9159156; PMCID: PMC20862.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    67. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol. 1997 May; 10(5):877-84. Jungwirth A, Schally A, Nagy A, Pinski J, Groot K, Galvan G, Szepeshazi K, Halmos G. PMID: 21533457.
      View in: PubMed   Mentions: 3     Fields:    
    68. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer. 1997; 75(11):1585-92. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P, Vadillo-Buenfil M. PMID: 9184172; PMCID: PMC2223520.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    69. Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int J Oncol. 1996 Dec; 9(6):1099-105. Pinski J, Schally A, Jungwirth A, Groot K, Halmos G, Armatis P, Zarandi M, Vadillobuenfil M. PMID: 21541617.
      View in: PubMed   Mentions: 20     Fields:    
    70. Effect of chronic administration of a new potent agonist of GH-RH(1-29)NH2 on linear growth and GH responsiveness in rats. Regul Pept. 1996 Sep 16; 65(3):197-201. Pinski J, Izdebski J, Jungwirth A, Groot K, Schally AV. PMID: 8897642.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    71. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology. 1996 Aug; 137(8):3430-6. Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS, Schally AV. PMID: 8754771.
      View in: PubMed   Mentions: 14     Fields:    Translation:Animals
    72. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci U S A. 1996 Mar 19; 93(6):2398-402. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K. PMID: 8637885; PMCID: PMC39808.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    73. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer. 1996 Mar 15; 65(6):870-4. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. PMID: 8631606.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    74. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst. 1995 Dec 06; 87(23):1787-94. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P. PMID: 7473836.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    75. Terminology for luteinizing hormone-releasing hormone antagonists. Fertil Steril. 1995 Jul; 64(1):226. Schally AV, Halmos G, Pinski J. PMID: 7789575.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    76. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A. 1995 May 23; 92(11):4872-6. Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. PMID: 7761415; PMCID: PMC41809.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    77. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75). Int J Pept Protein Res. 1995 May; 45(5):410-7. Pinski J, Schally AV, Yano T, Groot K, Srkalovic G, Serfozo P, Reissmann T, Bernd M, Deger W, Kutscher B, et al. PMID: 7591480.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    78. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A. 1994 Dec 06; 91(25):12298-302. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV. PMID: 7991622; PMCID: PMC45424.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    79. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res. 1994 Nov 15; 54(22):5895-901. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. PMID: 7954420.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    80. Treatment with luteinizing-hormone-releasing hormone antagonist sb-75 decreases levels of epidermal growth-factor receptor and its messenger-RNA in ov-1063 human epithelial ovarian-cancer xenografts in nude-mice. Int J Oncol. 1994 Nov; 5(5):1031-5. Shirahige Y, Cook C, Pinski J, Halmos G, Nair R, Schally A. PMID: 21559676.
      View in: PubMed   Mentions: 3     Fields:    
    81. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer. 1994 Nov; 70(5):886-92. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ. PMID: 7947094; PMCID: PMC2033546.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    82. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer. 1994 Oct 01; 59(1):51-5. Pinski J, Reile H, Halmos G, Groot K, Schally AV. PMID: 7927904.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    83. Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Lett. 1994 Sep 30; 85(1):111-8. Halmos G, Pinski J, Szoke B, Schally AV. PMID: 7923093.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    84. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A. 1994 Jul 19; 91(15):7090-4. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. PMID: 7518926; PMCID: PMC44344.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    85. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer. 1994 May 15; 57(4):574-80. Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV. PMID: 7910153.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    86. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1994 Mar 01; 91(5):1701-5. Yano T, Pinski J, Radulovic S, Schally AV. PMID: 8127868; PMCID: PMC43231.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    87. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer. 1994 Feb 15; 73(4):1229-38. Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV. PMID: 8313327.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    88. Somatostatin receptor expression in lung cancer. Eur J Cancer. 1994; 30A(11):1682-7. O'Byrne KJ, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV, Carney DN. PMID: 7833144.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    89. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res. 1994 Jan 01; 54(1):169-74. Pinski J, Reile H, Halmos G, Groot K, Schally AV. PMID: 7903203.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    90. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. Biomed Pharmacother. 1994; 48(10):465-72. Shirahige Y, Cai RZ, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV. PMID: 7858155.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    91. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int J Cancer. 1993 Dec 02; 55(6):963-7. Pinski J, Schally AV, Halmos G, Szepeshazi K. PMID: 7902829.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    92. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Cancer. 1993 Dec 01; 72(11):3263-70. Pinski J, Halmos G, Szepeshazi K, Schally AV. PMID: 8242552.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    93. Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486. J Clin Endocrinol Metab. 1993 Nov; 77(5):1388-92. Pinski J, Halmos G, Shirahige Y, Wittliff JL, Schally AV. PMID: 8077338.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    94. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett. 1993 Jul 30; 71(1-3):189-96. Pinski J, Halmos G, Schally AV. PMID: 8103419.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    95. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75). J Androl. 1993 May-Jun; 14(3):164-9. Pinski J, Yano T, Szepeshazi K, Groot K, Schally AV. PMID: 8407570.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    96. Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats. Int J Pept Protein Res. 1993 Mar; 41(3):246-9. Pinski J, Yano T, Groot K, Zsigo J, Rekasi Z, Comaru-Schally AM, Schally AV. PMID: 8463048.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    97. Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone. Int J Pept Protein Res. 1993 Feb; 41(2):162-8. Groot K, Csernus VJ, Pinski J, Zsigo J, Rekasi Z, Zarandi M, Schally AV. PMID: 8458690.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    98. Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats. Int J Pept Protein Res. 1993 Jan; 41(1):66-73. Pinski J, Yano T, Janaky T, Nagy A, Juhasz A, Bokser L, Groot K, Schally AV. PMID: 8436447.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    99. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate. 1993; 23(2):165-78. Pinski J, Schally AV, Yano T, Szepeshazi K, Halmos G, Groot K, Comaru-Schally AM, Radulovic S, Nagy A. PMID: 8378189.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    100. Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. Neuroendocrinology. 1992 Dec; 56(6):831-7. Pinski J, Yano T, Schally AV. PMID: 1369591.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    101. Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties. Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10203-7. Janáky T, Juhász A, Rékási Z, Serfözö P, Pinski J, Bokser L, Srkalovic G, Milovanovic S, Redding TW, Halmos G, et al. PMID: 1332035; PMCID: PMC50306.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    102. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration. Regul Pept. 1992 Oct 13; 41(3):185-93. Pinski J, Yano T, Rekasi Z, Cai RZ, Radulovic S, Schally AV. PMID: 1438988.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    103. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats. Am J Physiol. 1992 Oct; 263(4 Pt 1):E712-7. Pinski J, Yano T, Groot K, Cai RZ, Radulovic S, Schally AV. PMID: 1415689.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    104. Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats. Peptides. 1992 Sep-Oct; 13(5):905-11. Pinski J, Yano T, Groot K, Milovanovic S, Schally AV. PMID: 1336188.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    105. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res. 1992 Aug 15; 52(16):4545-7. Yano T, Pinski J, Groot K, Schally AV. PMID: 1643647.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    106. Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs. Proc Soc Exp Biol Med. 1992 May; 200(1):49-56. Pinski J, Milovanovic S, Yano T, Hamaoui A, Radulovic S, Cai RZ, Schally AV. PMID: 1349189.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    107. Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides. 1992 Mar-Apr; 13(2):267-71. Cai RZ, Radulovic S, Pinski J, Nagy A, Redding TW, Olsen DB, Schally AV. PMID: 1409006.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    108. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Prostate. 1992; 20(4):297-310. Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV. PMID: 1351672.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    109. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat. 1992; 21(1):35-45. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV. PMID: 1391973.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    110. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. Prostate. 1992; 20(3):213-24. Pinski J, Yano T, Miller G, Schally AV. PMID: 1533453.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    111. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. Int J Pept Protein Res. 1991 Dec; 38(6):593-600. Radulovic S, Cai RZ, Serfozo P, Groot K, Redding TW, Pinski J, Schally AV. PMID: 1726427.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    Jacek's Networks
    Concepts (377)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (36)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.